Fourteenth breakthrough therapy designation granted by FDA across the oncology portfolio of Daiichi Sankyo
In collaboration with the Gates Foundation, Merck advances MK-8527 pre-exposure prophylaxis (PrEP) clinical trials globally
The FDA set a target action date of April 28, 2026, under the Prescription Drug User Fee Act
Additional data will be presented on a once-weekly oral combination of islatravir and ulonivirine (ISL/ULO) for HIV-1 treatment
WINREVAIR significantly reduced the risk of clinical worsening events in recently diagnosed PAH patients over 70 percent of whom were on double background therapy
Enflosina is a long-acting monoclonal antibody that provides direct protection for up to 5 months
First pivotal Phase 3 trial to show superiority of Keytruda plus a TROP2 antibody-drug conjugate, Trodelvy, versus standard of care in first-line metastatic TNBC
Manageable safety profile and encouraging antitumor activity observed for MK-1084 in KANDLELIT-001, both as a monotherapy and in studied combinations
The decision to withdraw the BLA is based on topline overall survival (OS) results from the confirmatory HERTHENA-Lung02 Phase 3 trial where OS did not meet statistical significance
EC decision marks the fourth approval for CAPVAXIVE for pneumococcal vaccination in adults
Subscribe To Our Newsletter & Stay Updated
